Phage Display Isolation of Antibodies against Antigenically Conserved Membrane Pr

Information

  • Research Project
  • 8309899
  • ApplicationId
    8309899
  • Core Project Number
    R43GM101718
  • Full Project Number
    1R43GM101718-01
  • Serial Number
    101718
  • FOA Number
    PA-11-096
  • Sub Project Id
  • Project Start Date
    8/1/2012 - 12 years ago
  • Project End Date
    1/31/2014 - 10 years ago
  • Program Officer Name
    CHIN, JEAN
  • Budget Start Date
    8/1/2012 - 12 years ago
  • Budget End Date
    1/31/2014 - 10 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
  • Award Notice Date
    6/26/2012 - 12 years ago
Organizations

Phage Display Isolation of Antibodies against Antigenically Conserved Membrane Pr

DESCRIPTION (provided by applicant): We propose to use a novel technology, the Lipoparticle, to capture and concentrate structurally intact membrane proteins in a format amenable to phage panning for MAb isolation. The use of Lipoparticles to pan phage display libraries represents a valuable approach for obtaining antibodies against conserved membrane protein antigens because 1) Lipoparticles contain high concentrations of conformationally-intact target receptors, 2) target receptors within Lipoparticles are not exposed to adjuvants or biologically destructive environments so remain structurally intact, and 3) target receptors with high sequence conservation across species can be used as targets. PUBLIC HEALTH RELEVANCE: This proposal will result in monoclonal antibodies against important membrane protein targets for therapeutic development, diagnostics, and biomedical research. Lipoparticles optimized as panning reagents will be developed as a commercial product, and Lipoparticle-derived MAbs against biomedically important membrane protein targets will be licensed for therapeutic development or diagnostic use, or enter the commercial market as research reagents.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    214214
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:214214\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INTEGRAL MOLECULAR
  • Organization Department
  • Organization DUNS
    034055645
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191045504
  • Organization District
    UNITED STATES